Skin & HairNot FDA ApprovedCommunity Reported

Matrixyl 3000

Also known as Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7

A combination of Pal-GHK (collagen synthesis) and Pal-GQPR (anti-inflammatory) for superior anti-aging effects. Studies show superior wrinkle reduction versus original Matrixyl.

Cosmetic use - Widely available

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

2-8% in formulations

Frequency

Twice daily

Duration

Ongoing use for maintained effects

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 2-8% in formulations via Topical (serums, creams), Twice daily. Dose range: 2-8% concentration. Duration: Ongoing use for maintained effects.

Timing & Administration

Administer via Topical (serums, creams). Frequency: Twice daily.

Mechanism of Action

Combines Pal-GHK (collagen synthesis) with Pal-GQPR (anti-inflammatory) to stimulate collagen production while reducing age-accelerating inflammation with synergistic effects.

Research Summary

Evidence level: community reported. Clinical status: Cosmetic use - Widely available.

Side Effects & Safety

Important Warnings

  • Avoid mixing with strong acids
Temporary stinging (first week)
may trigger breakouts in acne-prone skin

References

No references available.